<DOC>
	<DOCNO>NCT02561195</DOCNO>
	<brief_summary>This study investigate Clostridium difficile vaccine healthy adult age 65-85 year . Each subject initially receive 3 dos vaccine 1 2 vaccination schedule . The study assess safety tolerability vaccine well subject ' immune response vaccine . One year third dose subject receive placebo randomize receive fourth dose . Subjects follow 4 year third vaccination .</brief_summary>
	<brief_title>A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 85 Years</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male female subject Aged 65 85 year Additional Inclusion Criteria extension Stage : Receipt 3 dos C difficile vaccine ( 100 µg 200 µg antigen dose level ) original portion study . Proven suspect prior episode Clostridium difficile associate diarrhea Unstable chronic medical condition Disease require significant change therapy hospitalization worsen disease within 8 week receipt study vaccine Serious chronic disorder Congenital acquire immunodeficiency disorder Rheumatologic disorder illnesses require chronic treatment know immunosuppressant medication . Active treat leukemia lymphoma bone marrow disorder Any contraindication vaccination vaccine component include previous anaphylactic reaction vaccine vaccinerelated component Additional Exclusion Criteria Extension Stage : Subjects originally randomize placebo original portion study . Subjects already complete Visit 9 prior study unblinding .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Clostridium difficile , Vaccine .</keyword>
</DOC>